Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4482137 | 0.91 | KDM1A (0.48) | SIGMAR1KDM1AMAOAMAOBMEN1 | |
| SCHEMBL23023136 | 0.90 | HTR5A (0.50) | SIGMAR1MEN1KMT2ATDP1 | |
| SCHEMBL22495345 | 0.88 | SIGMAR1 (0.63) | SIGMAR1MAOAMEN1KMT2ATDP1 | |
| SCHEMBL10425868 | 0.84 | SIGMAR1 (0.73) | SIGMAR1MAOAMEN1KMT2ATDP1 | |
| SCHEMBL23022866 | 0.84 | SIGMAR1 (0.69) | SIGMAR1MAOAMEN1KMT2ATDP1 | |
| SCHEMBL23023029 | 0.83 | SIGMAR1 (0.77) | SIGMAR1KDM1AMAOAMAOBMEN1 | |
| SCHEMBL21254320 | 0.83 | CXCR4 (0.59) | — | |
| SCHEMBL23023177 | 0.83 | SIGMAR1 (0.77) | SIGMAR1KDM1AMAOAMAOBMEN1 | |
| SCHEMBL23023089 | 0.81 | SIGMAR1 (0.54) | SIGMAR1MEN1KMT2ATDP1 | |
| SCHEMBL26644568 | 0.80 | CHRM2 (0.53) | MEN1KMT2ACHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | TRMT1, AARS1, GARS1 | SIGMAR1 2321/4885KDM1A 1628/4885MAOA 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.